Literature DB >> 26876812

Plasma total C-terminal agrin fragment (tCAF) as a marker for kidney function in patients with chronic kidney disease.

Dominik Steubl, Marcel Roos, Stefan Hettwer, Robin Satanovskij, Susanne Tholen, Ming Wen, Christoph Schmaderer, Anna-Lena Hasenau, Peter Luppa, Lynne Stecher, Uwe Heemann, Lutz Renders.   

Abstract

BACKGROUND: Total C-terminal agrin fragment (tCAF) is a new biomarker that was previously correlated with kidney function. This article studies the validity of tCAF as a biomarker for kidney function in chronic kidney disease (CKD).
METHODS: Plasma tCAF, serum creatinine (Cr), cystatin C (CyC), blood urea-nitrogen (BUN) concentrations and estimated glomerular filtration rate (eGFR CKD-EPIcrea-cystatin) were assessed in 426 individuals [71 without CKD (CKD 0°) and 355 CKD patients]. In addition to descriptive statistics, univariate correlation between tCAF and biomarkers/eGFR was calculated; multiple linear regression modeling was applied between logarithmic (log) tCAF and log eGFR and adjusted for demographic data. The same methods were used to analyze the association of demographic factors and the different biomarkers adjusted for eGFR.
RESULTS: Mean tCAF levels were 1012.2±789.9 pM. tCAF correlated with all biomarkers/eGFR in univariate analysis (eGFR: r=-0.77, Cr: r=0.74, BUN: r=0.66, CyC: r=0.75). Linear regression modeling revealed an excellent coefficient estimate between log tCAF and log eGFR (CKD-EPIcrea-cystatin) (-0.91, p<0.001). tCAF was the parameter least associated with demographic parameters in both univariate and multivariate regression modeling (only with age, coefficient estimate r=-0.159, p=0.001 in multivariate regression).
CONCLUSIONS: In conclusion, tCAF is a promising biomarker for the assessment of kidney function in CKD patients showing an excellent correlation with eGFR and being less influenced by demographic parameters compared to conventional biomarkers. These preliminary results encourage further evaluation of tCAF in larger CKD cohorts and other clinical settings such as acute renal failure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26876812     DOI: 10.1515/cclm-2015-1027

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  The Reference Intervals for Serum C-Terminal Agrin Fragment in Healthy Individuals and as a Biomarker for Renal Function in Kidney Transplant Recipients.

Authors:  Dan Yu; Hai-Xia Li; Yi Liu; Ze-Wei Ying; Jing-Jing Guo; Chen-Ying Cao; Jia Wang; Yuan-Fang Li; Hui-Rong Yang
Journal:  J Clin Lab Anal       Date:  2016-09-17       Impact factor: 2.352

2.  Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial.

Authors:  Xia Jiang; Fen Ji; Zhi-Wei Chen; Qiao-Lin Huang
Journal:  Int Urol Nephrol       Date:  2016-07-05       Impact factor: 2.370

3.  Plasma C-terminal agrin fragment and rapid kidney function decline in chronic kidney disease patients.

Authors:  Georg Lorenz; Stefan Hettwer; Wendy McCallum; Susanne Angermann; Ming Wen; Christoph Schmaderer; Uwe Heemann; Marcel Roos; Lutz Renders; Dominik Steubl
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Circulating C-Terminal Agrin Fragment: A Potential Marker for Sarcopenia Among Type 2 Diabetes.

Authors:  Pranathi Racha; Sumithra Selvam; Beena Bose; Ganapathi Bantwal; Sucharita Sambashivaiah
Journal:  Indian J Endocrinol Metab       Date:  2022-09-20

Review 5.  Developing a toolkit for the assessment and monitoring of musculoskeletal ageing.

Authors:  Graham J Kemp; Fraser Birrell; Peter D Clegg; Daniel J Cuthbertson; Giuseppe De Vito; Jaap H van Dieën; Silvia Del Din; Richard Eastell; Patrick Garnero; Katarzyna Goljanek-Whysall; Matthias Hackl; Richard Hodgson; Malcolm J Jackson; Sue Lord; Claudia Mazzà; Anne McArdle; Eugene V McCloskey; Marco Narici; Mandy J Peffers; Stefano Schiaffino; John C Mathers
Journal:  Age Ageing       Date:  2018-09-01       Impact factor: 10.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.